Prospective cohort study on the outcomes of hepatitis C virus-related cirrhosis in South Korea

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 8, 2015, Pages 1281-1287

  Lee, Sang Soo ^a   Jeong, Sook Hyang ^b   Jang, Eun Sun ^b   Kim, Young Seok ^c   Lee, Youn Jae ^d   Jung, Eun Uk ^d   Kim, In Hee ^e   Bae, Si Hyun ^f   Lee, Han Chu ^g   Kee, Mee Kyung ^h   Kang, Chun ^h  

^a Gyeongsang National University School of Medicine   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Soonchunhyang University College of Medicine   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Chonbuk National University Medical School and Hospital   (South Korea)

^f The Catholic University of Korea   (South Korea)

^g University of Ulsan College of Medicine   (South Korea)

^h Korea National Institute of Health   (South Korea)

Author keywords

Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Liver cirrhosis; Mortality

Indexed keywords

HEPATITIS B ANTIBODY; SERUM ALBUMIN; HEPATITIS B SURFACE ANTIGEN;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; ASCITES; CANCER INCIDENCE; CANCER MORTALITY; COHORT ANALYSIS; FEMALE; FOLLOW UP; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SOUTH KOREA; UNIVERSITY HOSPITAL; AGED; CLINICAL TRIAL; COMPLICATION; IMMUNOLOGY; INCIDENCE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODEL; TIME FACTOR;

AGED; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS C; HUMANS; INCIDENCE; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REPUBLIC OF KOREA; SERUM ALBUMIN; TIME FACTORS;

EID: 84937401970     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12950     Document Type: Article

References (50)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect. Dis. 2005; 5: 558-567.
2. Thein HH, Yi Q, Dore GJ, Krahn MD. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-431.
3. Liang TJ, Heller T. Pathogenesis of hepatitis C-associated hepatocellular carcinoma. Gastroenterology 2004; 127: S62-71.
4. Lee SS, Byoun YS, Jeong SH etal. Type and cause of liver disease in Korea: single-center experience, 2005-2010. Clin. Mol. Hepatol. 2012; 18: 309-315.
5. Seong MH, Kil H, Kim YS etal. Clinical and epidemiological features of hepatitis C virus infection in South Korea: a prospective, multicenter cohort study. J. Med. Virol. 2013; 85: 1724-1733.
6. Wai CT, Greenson JK, Fontana RJ etal. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38: 518-526.
7. Colli A, Fraquelli M, Casazza G etal. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am. J. Gastroenterol. 2006; 101: 513-523.
8. Statics Korea. Korean statistical information service. 2012. Available from URL: http://www.kosis.kr/
9. Benvegnu L, Gios M, Boccato S, Alberti A. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 2004; 53: 744-749.
10. Sangiovanni A, Prati GM, Fasani P etal. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310.
11. Toshikuni N, Izumi A, Nishino K etal. Comparison of outcomes between patients with alcoholic cirrhosis and those with hepatitis C virus-related cirrhosis. J. Gastroenterol. Hepatol. 2009; 24: 1276-1283.
12. Okanoue T, Itoh Y, Minami M etal. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J. Hepatol. 1999; 30: 653-659.
13. Shiratori Y, Ito Y, Yokosuka O etal. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann. Intern. Med. 2005; 142: 105-114.
14. Yoshida H, Shiratori Y, Moriyama M etal. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann. Intern. Med. 1999; 131: 174-181.
15. Kobayashi M, Ikeda K, Hosaka T etal. Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections. J. Med. Virol. 2006; 78: 459-465.
16. Asahina Y, Tsuchiya K, Tamaki N etal. Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. Hepatology 2010; 52: 518-527.
17. Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment. Pharmacol. Ther. 2010; 32: 344-355.
18. Hu KQ, Tong MJ. The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States. Hepatology 1999; 29: 1311-1316.
19. Serfaty L, Aumaitre H, Chazouilleres O etal. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology 1998; 27: 1435-1440.
20. Bruno S, Zuin M, Crosignani A etal. Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study. Am. J. Gastroenterol. 2009; 104: 1147-1158.
21. Degos F, Christidis C, Ganne-Carrie N etal. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 2000; 47: 131-136.
22. Nguyen MH, Whittemore AS, Garcia RT etal. Role of ethnicity in risk for hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis. Clin. Gastroenterol. Hepatol. 2004; 2: 820-824.
23. Lee MH, Yang HI, Lu SN etal. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J. Clin. Oncol. 2010; 28: 4587-4593.
24. Kim YS, Um SH, Ryu HS etal. The prognosis of liver cirrhosis in recent years in Korea. J. Korean Med. Sci. 2003; 18: 833-841.
25. Sinn DH, Paik SW, Kang P etal. Disease progression and the risk factor analysis for chronic hepatitis C. Liver Int. 2008; 28: 1363-1369.
26. Ikeda K, Arase Y, Saitoh S etal. Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. J. Hepatol. 2006; 44: 1089-1097.
27. Fattovich G, Giustina G, Degos F etal. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-472.
28. Chiba T, Matsuzaki Y, Abei M etal. Multivariate analysis of risk factors for hepatocellular carcinoma in patients with hepatitis C virus-related liver cirrhosis. J. Gastroenterol. 1996; 31: 552-558.
29. Aizawa Y, Shibamoto Y, Takagi I, Zeniya M, Toda G. Analysis of factors affecting the appearance of hepatocellular carcinoma in patients with chronic hepatitis C. A long term follow-up study after histologic diagnosis. Cancer 2000; 89: 53-59.
30. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J. Hepatol. 2009; 50: 1142-1154.
31. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004; 126: 460-468.
32. Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005; 54: 533-539.
33. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N. Engl. J. Med. 1999; 341: 22-26.
34. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int. J. Cancer 1998; 75: 347-354.
35. Shi Y, Wu YH, Wu W, Zhang WJ, Yang J, Chen Z. Association between occult hepatitis B infection and the risk of hepatocellular carcinoma: a meta-analysis. Liver Int. 2012; 32: 231-240.
36. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127: S35-50.
37. Gramenzi A, Andreone P, Fiorino S etal. Impact of interferon therapy on the natural history of hepatitis C virus related cirrhosis. Gut 2001; 48: 843-848.
38. Bruno S, Stroffolini T, Colombo M etal. Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587.
39. Dienstag JL, Ghany MG, Morgan TR etal. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology 2011; 54: 396-405.
40. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46: 1350-1356.
41. Yu ML, Lin SM, Lee CM etal. A simple noninvasive index for predicting long-term outcome of chronic hepatitis C after interferon-based therapy. Hepatology 2006; 44: 1086-1097.
42. Cho EJ, Jeong SH, Han BH, Lee SU, Yun BC, Park ET. Hepatitis C virus (HCV) genotypes and the influence of HCV subtype 1b on the progression of chronic hepatitis C in Korea: a single center experience. Clin. Mol. Hepatol. 2012; 18: 219-224.
43. Veldt BJ, Chen W, Heathcote EJ etal. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-1862.
44. Squadrito G, Cacciola I, Alibrandi A, Pollicino T, Raimondo G. Impact of occult hepatitis B virus infection on the outcome of chronic hepatitis C. J. Hepatol. 2013; 59: 696-700.
45. Raimondo G, Allain JP, Brunetto MR etal. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J. Hepatol. 2008; 49: 652-657.
46. Candotti D, Allain JP. Transfusion-transmitted hepatitis B virus infection. J. Hepatol. 2009; 51: 798-809.
47. Kim MJ, Kwon OS, Chung NS etal. [The significance of anti-HBc and occult hepatitis B virus infection in the occurrence of hepatocellular carcinoma in patients with HBsAg and anti-HCV negative alcoholic cirrhosis]. Korean J. Hepatol. 2008; 14: 67-76.
48. Planas R, Balleste B, Alvarez MA etal. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J. Hepatol. 2004; 40: 823-830.
49. Singal AK, Singh A, Jaganmohan S etal. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin. Gastroenterol. Hepatol. 2010; 8: 192-199.
50. van der Meer AJ, Veldt BJ, Feld JJ etal. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA 2012; 308: 2584-2593.